MD CJC-1295

RESEARCH DIGEST · CITATIONS

CJC-1295 References and Citations

Every figure on this site maps to one of these studies. The human pharmacokinetic record, the preclinical mechanism work, and the analytical literature, each with a DOI or PubMed link.

Back to the researchDAC vs no-DAC

How to Read This List

These are the CJC-1295 references behind every quantitative claim on this site. The list separates into three groups: the early human pharmacokinetic studies that established the GH/IGF-1 kinetics and the DAC half-life [1][3][5], the preclinical work that identified the bioconjugate and demonstrated once-daily growth normalization [2][4], and the analytical and anti-doping literature plus recent reviews that document the compound's detection science and its place in the GHRH-analog class [6][7][8][9][10][11][12][13][14][15].

Where a study is paywalled, the PubMed abstract and DOI remain freely resolvable. The full citations follow in the references list below.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormone analogs. J Pharm Biomed Anal. 2022. ↗
  8. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  9. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS. Anal Bioanal Chem. 2016. ↗
  10. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing. Oncotarget. 2016. ↗
  11. GHRH expression plasmid improves osteoporosis and skin damage in aged mice. Growth Horm IGF Res. 2021. ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  13. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control. J Mass Spectrom. 2024. ↗
  14. Analysis of growth hormone releasing hormone and its analogs in urine using nano-LC-MS. J Pharm Biomed Anal. 2025. ↗
  15. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. ↗